Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Life Sciences
Gustiananda, Marsia
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
What do T cells see in SARS-CoV2? Gustiananda, Marsia
Indonesian Journal of Life Sciences 2020: IJLS Vol 02 No .01
Publisher : Indonesia International Institute for Life Sciences

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (875.758 KB) | DOI: 10.54250/ijls.v2i1.36

Abstract

The current epidemic caused by a novel coronavirus SARS-CoV2 as well as two previously documented pandemic caused by SARS-CoV and MERS-CoV imposes that a spillover of an animal coronavirus to humans is a continuous threat. The zoonotic nature of the infection contributes to the unpredictability of the pandemic. In such situations, the availability of the ‘off the shelf’ vaccines that target the conserved region of the coronavirus might help in preventing the spread of the diseases. Therefore, efforts to generate such vaccines should be considered as a priority. The whole genome of SARS-CoV2 is readily available in the public database one month after the first case was identified. The platform technology known as the “genome to vaccine” approach would provide useful start to identify parts of the virus proteome which can be the candidate for vaccine components. This study used an immunoinformatic approach to identify T cell epitopes from SARS-CoV2 ORF1ab polyprotein in an attempt to design a genome-derived epitope-based universal coronavirus vaccine.
In-Silico Design of a PIN1/ABCC5-Targeted Multi-Epitope Vaccine for Nasopharyngeal Cancer Ashiila, Putri; Gustiananda, Marsia
Indonesian Journal of Life Sciences 2026: IJLS Vol 08 No.01
Publisher : Universitas Bio Scientia Internasional Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.54250/ijls.v8i01.218

Abstract

Nasopharyngeal Carcinoma (NPC) is a rare malignancy. However, it is the fourth most common cancer affecting both sexes in Indonesia, and research on NPC remains limited. NPC is related to Epstein-Barr Virus (EBV) infection, making it a potential target for immunotherapy strategies. Developing a multi-epitope-based NPC vaccine targeting tumor-overexpressed antigens may evoke an immune response against cancer cells and benefit patients with advanced cancer stages or those resistant to treatment. Four cytotoxic (CTL) and one helper T-cell (HTL) epitopes from PIN1 were identified using NetMHCpan and NetMHCIIpan algorithms, respectively. Whereas from ABCC5, five CTL and four HTL epitopes were identified using the same algorithms. These epitopes were found to have good coverage across the Indonesian population, with population coverage analysis showing 99% coverage for human leukocyte antigen (HLA) Class I and 95% for HLA Class II. Having fulfilled other criteria such as immunogenicity, IFN-γ-inducing ability, and non-homology to human peptides, the epitopes were assembled into a vaccine construct together with E. coli and Bacillus as adjuvants and appropriate linkers. The construct was shown to have good physicochemical characteristics and the ability to induce CTL and HTL responses, which stem from the engagement of the vaccine with toll-like receptor 4 (TLR4) as revealed by docking simulations.
Co-Authors Ashiila, Putri